Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

3.1K
Commitment is the  process whereby stem cells:
3.1K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling01:11

Aryldiazonium Salts to Azo Dyes: Diazo Coupling

3.1K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relapse risk after FLAMSA RIC based allogeneic hematopoietic stem cell transplantation in heavily pretreated AML patients.

Bone marrow transplantation·2026
Same author

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells.

Bone marrow transplantation·2026
Same author

Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs.

Blood·2026
Same author

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes.

Blood cancer journal·2026

Related Experiment Video

Updated: Aug 30, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.0K

How Azanucleosides Affect Myeloid Cell Fate.

Anna Stein1, Uwe Platzbecker1, Michael Cross1

  • 1Department of Hematology, Cell Therapy and Hemostaseology, Leipzig University Hospital, 04103 Leipzig, Germany.

Cells
|August 26, 2022
PubMed
Summary

Decitabine and azacytidine, used for myeloid cancers, have distinct actions: decitabine targets DNA methylation, while azacytidine targets RNA methylation. Understanding these mechanisms is crucial for effective combination therapies.

Keywords:
azacytidinedecitabineepigeneticshematopoiesishypomethylating agentsmyeloid neoplasia

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Experiment Videos

Last Updated: Aug 30, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.0K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Area of Science:

  • Epigenetics
  • Hematopoiesis
  • Cancer Biology

Background:

  • Azanucleosides like decitabine and azacytidine are standard treatments for myeloid neoplasia.
  • Previously considered interchangeable hypomethylating agents, they possess distinct mechanisms of action.
  • Decitabine primarily affects DNA methylation, whereas azacytidine impacts RNA methylation.

Purpose of the Study:

  • To review the role of DNA methylation in stem cell lineage commitment during hematopoiesis.
  • To explore how mutations in epigenetic regulators (e.g., DNMT3A, TET2) contribute to neoplastic progression.
  • To discuss the broader efficacy of azanucleosides beyond epigenetic mutations and highlight RNA methylation's role.

Main Methods:

  • Literature review and synthesis of existing research on azanucleosides.
  • Analysis of DNA and RNA methylation mechanisms in normal and malignant hematopoiesis.
  • Examination of epigenetic regulator mutations and their impact on clonal expansion.

Main Results:

  • Decitabine and azacytidine exhibit differential effects on DNA and RNA methylation, respectively.
  • Mutations in epigenetic regulators like DNMT3A and TET2 are implicated in myeloid neoplasia development.
  • Azacytidine's efficacy extends to processes involving RNA methylation, including stress response and lineage commitment.

Conclusions:

  • Azanucleosides have diverse mechanisms beyond simple hypomethylation, impacting both DNA and RNA.
  • Considering these multiple modes of action is essential for optimizing future combination therapies.
  • Further research into RNA methylation's role may reveal new therapeutic strategies for myeloid neoplasms.